BioSpace News Archive

Single Pass, a leading provider of innovative medical devices, is pleased to announce an exclusive distribution agreement with Mermaid Medical Group, a renowned global medical technology company.

AIM ImmunoTech Inc. today announced that the first subject has been enrolled at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM’s Ampligen ® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi ® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”).

Bold Therapeutics presented positive Phase 2 safety and efficacy data in advanced metastatic colorectal cancer (mCRC) patients treated with BOLD-100 in combination with FOLFOX previously treated with FOLFOX/CAPOX at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on January 18-20, 2024.

Pi-Cardia Ltd. announced today it received Breakthrough Device Designation from the US Food and Drug Administration for ShortCut™ - the world’s first dedicated leaflet modification device facilitating valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures in patients at risk of coronary obstruction.

MCRA, LLC is pleased to announce its role in providing strategic due diligence support for Anzu Special Acquisition Corp I, ahead of the recent deal with Envoy Medical .

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce the Company has closed a non-brokered private placement (the “Offering”) of unsecured convertible debentures (each, a “Debenture”).

Brenus Pharma announces the financing of nearly 5 million euros for its STC-1010 project as the winner of the “Innovations in Biotherapy and Bioproduction” call for proposals from France 2030.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) clearance for the manual SmartTwist® MR Hand Drill and SmartTip® MR Drill Kit.

Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.

PDS Biotechnology Corporation announced the appointment of Kirk V. Shepard, M.D., as Chief Medical Officer, effective January 22, 2024.